



Understanding Protein Subunit COVID-19 Vaccines

Updated July 20, 2022

What You Need to Know

- Protein subunit COVID-19 vaccines contain pieces (proteins) of the virus that causes COVID-19; these proteins are called the “spike protein.”
- Protein subunit COVID-19 vaccines also contain another ingredient called an adjuvant that helps the immune system respond to that virus in the future.
- Once the immune system knows how to respond to the spike protein, the immune system will be able to respond quickly to the actual virus spike protein and protect you against COVID-19.
- Researchers have been studying protein subunit vaccines for a long time and this type of vaccine has been in use for decades.
- Like all vaccines, protein subunit vaccines benefit people who get vaccinated by giving them protection against diseases like COVID-19 without risking the potentially serious consequences of getting sick.

The Novavax COVID-19 vaccine is a protein subunit COVID-19 vaccine that is authorized for use in the United States under Emergency Use Authorization. Learn more about [Novavax COVID-19 vaccine](#), including who can get it, doses, and ingredients.

How Protein Subunit COVID-19 Vaccines Work

Protein subunit vaccines contain pieces (proteins) of the virus that causes COVID-19. These virus pieces are the spike protein. The vaccine also contains another ingredient called an adjuvant that helps the immune system respond to that spike protein in the future. Once the immune system knows how to respond to the spike protein, the immune system will be able to respond quickly to the actual virus spike protein and protect you against COVID-19.

1. First, protein subunit COVID-19 vaccines are given in the upper arm muscle. After vaccination, nearby cells pick up these proteins.
2. Next, our [immune system](#) recognizes that these proteins do not belong there. Another ingredient in the vaccine, the adjuvant, helps our immune system to produce antibodies and activate other immune cells to fight off what it thinks is an infection. This is what your body might do if you got sick with COVID-19.
3. At the end of the process, our bodies have learned how to help protect against future infection with the virus that causes COVID-19. The benefit is that people get this protection from a vaccine, without ever having to risk the potentially serious consequences of getting sick with COVID-19. Many [side effects](#) from getting the vaccine are normal signs the body is building protection.

Facts About Protein Subunit COVID-19 Vaccines

Protein subunit COVID-19 vaccines cannot cause COVID-19 or other illnesses.

- Protein subunit COVID-19 vaccines do **not** use any live virus.
- Protein subunit COVID-19 vaccines **cannot** cause infection with the virus that causes COVID-19 or other viruses.

They do not affect or interact with our DNA.

- The protein pieces do **not** enter the nucleus of the cell where our DNA (genetic material) is located, so they cannot change or influence our genes.

Protein Subunit COVID-19 Vaccines Have Been Rigorously Evaluated for Safety

COVID-19 vaccines are [safe](#) and [effective](#).

Protein subunit COVID-19 vaccines have been held to the same [rigorous safety and effectiveness standards](#) [↗](#) as all other types of vaccines in the United States. The only COVID-19 vaccines the Food and Drug Administration (FDA) makes available for use in the United States (by approval or emergency use authorization) are those that meet these standards.

Protein Subunit Vaccines Have Been Used for Years

More than 30 years ago, a hepatitis B vaccine became the first protein subunit vaccine to be approved for use in people in the United States. Another example of other protein subunit vaccines used in the United States today include acellular pertussis (whooping cough) vaccines.



For Healthcare and Public Health
[COVID-19 Clinical and Professional Resources](#)

More Information

[FDA’s Vaccine Development 101](#) [↗](#)

[FDA’s Emergency Use Authorization for Vaccines Explained](#) [↗](#)

[FDA Infographic: The Path for a COVID-19 Vaccine from Research to Emergency Use Authorization \[724 KB, 1 page\]](#) [↗](#)